Tailoring loco-regional therapy with neoadjuvant chemotherapy: Another step in the right direction

Annals of Surgical Oncology

Volumn 11, Issue 10, 2004, Pages 888-891

  Mamounas, Eleftherios P ^a,b  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^b Aultman Health Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; TAXANE DERIVATIVE;

ADJUVANT CHEMOTHERAPY; BREAST CANCER; CANCER RECURRENCE; CANCER SURGERY; CANCER THERAPY; EDITORIAL; HUMAN; MASTECTOMY; ADJUVANT THERAPY; BREAST TUMOR; CANCER STAGING; FEMALE; NOTE; PATHOLOGY; PROGNOSIS; SEGMENTAL MASTECTOMY; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; MASTECTOMY, SEGMENTAL; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS;

EID: 16544372569     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1245/ASO.2004.08.908     Document Type: Editorial

References (44)

1. Gianni L, Baselga J, Eiermann W, et al. First report of the European Cooperative Trial in operable breast cancer (ECTO): effects of primary systemic therapy (PST) on local-regional disease (abstract 132). Proc Am Soc Clin Oncol 2002;21:34a.
2. van der Hage JA, van de Velde CJ, Julien JP, et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001;19:4224-37.
3. Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997;15:2483-93.
4. Jacquillat C, Weil M, Baillet F, et al. Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer. Cancer 1990;66:119-29.
5. Bonadonna G, Veronesi U, Brambilla C, et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 1990;82:1539-45.
6. Tubiana-Hulin M, Malek M, Brifford M, et al. Preoperative chemotherapy of operable breast cancer (stage IIIA). Prognostic factors of distant recurrence. Eur J Cancer 1993;29A(Suppl 6):S76.
7. Smith IE, Jones AL, O'Brien ME et al. Primary medical (neoadjuvant) chemotherapy for operable breast cancer. Eur J Cancer 1993;29A:1796-9.
8. Cance WG, Carey LA, Calvo BF, et al. Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival. Ann Surg 2002;236:295-303.
9. Danforth DN, Jr., Zujewski J, O'Shaughnessy J et al. Selection of local therapy after neoadjuvant chemotherapy in patients with stage IIIA, B breast cancer. Ann Surg Oncol 1998;5:150-8.
10. Clark J, Rosenman J, Cance W, et al. Extending the indications for breast-conserving treatment to patients with locally advanced breast cancer. Int J Radiat Oncol Biol Phys 1998;42:345-50.
11. Schwartz GF, Birchansky CA, Komarnicky LT, et al. Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast. Cancer 1994;73:362-9.
12. Shen J, Valero V, Buchholz T, et al. Effective local control and long-term survival in patients with T4 locally advanced breast cancer treated with breast conservation therapy. Ann Surg Oncol 2004;11:854-60.
13. Esserman L, Hylton N, Yassa L, et al. Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging. J Clin Oncol 1999;17:110-9.
14. Cheung YC, Chen SC, Su MY, et al. Monitoring the size and response of locally advanced breast cancers to neoadjuvant chemotherapy (weekly paclitaxel and epirubicin) with serial enhanced MRI. Breast Cancer Res Treat 2003;78:51-8.
15. Wasser K, Klein SK, Fink C, et al. Evaluation of neoadjuvant chemotherapeutic response of breast cancer using dynamic MRI with high temporal resolution. Eur Radiol 2003;13:80-7.
16. Partridge SC, Gibbs JE, Lu Y, et al. Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. AJR Am J Roentgenol 2002;179:1193-9.
17. Esserman L, Kaplan E, Partridge S, et al. MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer. Ann Surg Oncol 2001;8:549-59.
18. Martincich L, Montemurro F, Cirillo S, et al. Role of magnetic resonance imaging in the prediction of tumor response in patients with locally advanced breast cancer receiving neoadjuvant chemotherapy. Radiol Med (Torino) 2003;106:51-8.
19. Kaplan E, Yu E, Tripathy D, et al. MRI patterns predict the ability to perform breast conservation following neoadjuvant chemotherapy for locally advanced breast cancer (abstract 101). Br Cancer Res Treat 2003;82(Suppl 1):S19.
20. Baron LF, Baron PL, Ackerman SJ, et al. Sonographically guided clip placement facilitates localization of breast cancer after neoadjuvant chemotherapy. AJR Am J Roentgenol 2000;174:539-40.
21. Alonso-Bartolome P, Ortega Garcia E, Garijo Ayensa F, et al. Utility of the tumor bed marker in patients with breast cancer receiving induction chemotherapy. Acta Radiol 2002;43:29-33.
22. Braeuning MP, Burke ET, Pisano ED. Embolization coils as tumor markers for mammography in patients undergoing neoadjuvant chemotherapy for carcinoma of the breast. AJR Am J Roentgenol 2000;174:251-2.
23. Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003;21:4165-74.
24. Gianni L, BJ, Eiermann W, et al. First report of the European Cooperative Trial in operable breast cancer (ECTO): effect of primary systemic therapy (abstract 132). Proc Am Soc Clin Oncol 2002;21:34a.
25. Mamounas EP. Sentinel lymph node biopsy after neoadjuvant systemic therapy. Surg Clin North Am 2003;83:931-42.
26. Xing Y, Ding D, Cox D, et al. Meta-analysis of sentinel lymph node biopsy following preoperative chemotherapy in patients with operable breast cancer (abstract 561). Proc Am Soc Clin Oncol 2004;23:17.
27. O'Hea BJ, Hill AD, El-Shirbiny AM, et al. Sentinel lymph node biopsy in breast cancer: initial experience at Memorial Sloan-Kettering Cancer Center. J Am Coll Surg 1998;186:423-7.
28. McMasters KM, Tuttle TM, Carlson DJ, et al. Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol 2000;18:2560-6.
29. Krag DN, Weaver DL, Alex JC, Fairbank JT. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol 1993;2:335-9; discussion 340.
30. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994;220:391-8; discussion 398-401.
31. Mamounas EP, Wang J, Bryant J, et al. Patterns of loco-regional failure (ERF) in patients receiving neoadjuvant chemotherapy (NC): results from NSABP B-18 (abstract 35). Breast Cancer Res Treat 2003:82(Suppl 1):S17.
32. Buchholz TA, Tucker SL, Masullo L, et al. Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation. J Clin Oncol 2002;20:17-23.
33. Buzdar AU, Hunt K, Smith T, et al. Significantly higher pathological complete remission (PCR) rate following neoadjuvant therapy with trastuzumab (H), paclitaxel (P), and anthracycline-containing chemotherapy (CT): initial results of a randomized trial in operable breast cancer (BC) with HER/2 positive disease (abstract 520). Proc Am Soc Clin Oncol 2004;23:7.
34. Aryus B, Audretsch W, Gogolin F, et al. Remission rates following preoperative chemotherapy and radiation therapy in patients with breast cancer. Strahlenther Onkol 2000;176:411-5.
35. Gerlach B, Audretsch W, Gogolin F, et al. Remission rates in breast cancer treated with preoperative chemotherapy and radiotherapy. Strahlenther Onkol 2003;179:306-11.
36. Mauriac L, MacGrogan G, Avril A, et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol 1999;10:47-52.
37. Scholl SM, Fourquet A, Asselain B, et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer 1994;30A:645-52.
38. Singletary SE. Minimally invasive surgery in breast cancer treatment. Biomed Pharmacother 2001;55:510-4.
39. Danforth DN, Jr, Aloj L, Carrasquillo JA, et al. The role of 18F-FDG-PET in the local/regional evaluation of women with breast cancer. Breast Cancer Res Treat 2002;75:135-46.
40. Michel SC, Keller TM, Frohlich JM, et al. Preoperative breast cancer staging: MR imaging of the axilla with ultrasmall superparamagnetic iron oxide enhancement. Radiology 2002;225:527-36.
41. Hurkmans CW, Borger JH, Rutgers EJ, van Tienhoven G. Quality assurance of axillary radiotherapy in the EORTC AMAROS trial 10981/22023: the dummy run. Radiother Oncol 2003;68:233-40.
42. Buchholz TA, Strom EA, McNeese MD, Hunt KK. Radiation therapy as an adjuvant treatment after sentinel lymph node surgery for breast cancer. Surg Clin North Am 2003;83:911-30.
43. Esserman L, Sepucha K, Ozanne E, Hwang ES. Applying the neoadjuvant paradigm to ductal carcinoma in situ. Ann Surg Oncol 2004;11(Suppl 1):28S-36S.
44. Hwang ES, Esserman L. Neoadjuvant hormonal therapy for ductal carcinoma in situ: trial design and preliminary results. Ann Surg Oncol 2004;11(Suppl 1):37S-43S.